Company attributes
Other attributes
Oxford BioMedica is a publicly traded, gene and cell therapy group based in Oxford, Oxforshire, UK. The company and its subsidiaries (the "Group") have build a lentiviral delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products, both in-house and with partners. Its portfolio ranges across the areas of oncology, opthalmology, and CNS disorders.
Within its pipeline, Oxford BioMedica has several proprietary products, partnered products, and IP enabled and royalty bearing products. Its proprietary products, which would either be spun-out or licensed out, include:
- OXB-202 - gene based treatment for corneal graft rejection. Phase 1/2 clinical studies are in preparation.
- OXB-302 - gene based immunotherapy targeting a range of cancers. Pre-clinical studies are complete.
- OXB-201 - gene therapy for wet AMD. Phase 1 clinical trials have been completed.
- OXB-204 - in pre-clinical studies
- OXB-208 - in pre-clinical studies
- OXB-103 - in pre-clinical studies
The company's partnered products include:
- AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
- SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
- SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.
Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.
